Sökresultat - "Rechallenge"

Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma

Shao, Keda^{Aff1, Aff2}, Zeng, Xiaohong^{Aff1, Aff2}, Hao, Yue^Aff2, Wang, Yanhua, Xu, Chunwei^{Aff3, Aff4, IDs1209402403597z_cor1}, Song, Zhengbo^{Aff1, Aff2, IDs1209402403597z_cor2}

Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis

Xinrong Chen, Ke Wang, Yongxin Liao, Chuangjie Zheng, Deyu Yang, Zhichao Li, Linzhu Zhai

electronic resource

Visa

Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study

Ken Horisaki, Shusuke Yoshikawa, Wataru Omata, Arata Tsutsumida, Yoshio Kiyohara

electronic resource

Visa; Visa; Visa

Evaluation of Oncolytic Virus-Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models

Veinalde, Rūta^Aff3

Engeland, Christine E.^Aff2, Walker, John M.^Aff1

Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study

xu, Manyi^Aff1, Wang, Yanhua^Aff1, Wang, Ke^Aff1, Hao, Yue^Aff3, Xu, Chunwei, Shi, Lei^{Aff1, Aff2}, Song, Zhengbo^{Aff1, Aff2, IDs10637024014837_cor1}

Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy

Lai, Kuan-Chang, Chen, Yen-Hao^{Aff2, Aff3}, Hung, Yi‑Ping^{Aff1, Aff4, Aff5}, Chiang, Nai-Jung^{Aff1, Aff4}, Chen, Ming‑Huang^{Aff1, Aff4, Aff5}, Chen, San-Chi^{Aff1, Aff4, Aff5, IDs12072024107289_cor1}

Efficacy and safety of rechallenge with [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer

Santo, Giulia^{Aff1, Aff2}, Di Santo, Gianpaolo, Sviridenko, Anna, Bayerschmidt, Steffen, Wirth, Lukas, Scherbauer, Fabian, Lehmann, Peter, von Guggenberg, Elisabeth, Decristoforo, Clemens, Heidegger-Pircher, Isabel, Bektic, Jasmin, Virgolini, Irene^{Aff1, IDs00259024069055_cor12}

Efficacy and safety of rechallenge [¹⁷⁷Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)

Rosar, Florian, Schuler, Joelle, Burgard, Caroline, Blickle, Arne, Bartholomä, Mark, Maus, Stephan, Petto, Sven, Khreish, Fadi^{Aff1, Aff2}, Schaefer, Andrea, Ezziddin, Samer^{Aff1, IDs00259024068254_cor10}

Effectiveness of trastuzumab deruxtecan rechallenge in a patient with HER2-positive metastatic breast cancer: a case report

Tanaka, Yuko^{Aff1, IDs13691024007230_cor1}, Ikeda, Naoya, Niho, Seiji, Ishida, Kazuyuki

Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window

Kaibo Ding, Dujiang Liu, Xinyue Li, Zhongsheng Peng, Lin Zhu, Yanjun Xu

electronic resource

Visa; Visa

Treatment rechallenge is safe and leads to better survival in pancreatic cancer patients with interstitial pneumonitis

Hung-Yuan Yu, Chun-Yang Lee, Yen-Chi Hu, Le-Gin Lin, Yee Chao, Chung-Pin Li

electronic resource

Visa

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial

Yaofei Jiang, Weixin Bei, Lin Wang, Nian Lu, Cheng Xu, Hu Liang, Liangru Ke, Yanfang Ye, Shuiqing He, Shuhui Dong, Qin Liu, Chuanrun Zhang, Xuguang Wang, Weixiong Xia, Chong Zhao, Ying Huang, Yanqun Xiang, Guoying Liu

electronic resource

Visa

Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons

Hui-Ai Zeng, Hui-Min Lv, Meng-Wei Zhang, Li-Min Niu, Jing Wang, Hui-Hui Sun, Zhen-Zhen Liu, Min Yan

electronic resource

Visa

Lenvatinib Monotherapy Versus Lenvatinib in Combination with PD-1 Blockades as Re-Challenging Treatment for Patients with Metastatic Osteosarcoma: A Real-World Study

Song G, Tang Q, Lu J, Xu H, Wang A, Deng C, Wu H, Hu J, Zhu X, Wang J

electronic resource

Visa; Visa

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study

Chenming Liu, Jintao Chen, Yuxing Liu

electronic resource

Visa

Type‑I AIE Photosensitizer Loaded Biomimetic System Boosting Cuproptosis to Inhibit Breast Cancer Metastasis and Rechallenge

Ning, Shipeng^{aff1, aff5}, Lyu, Meng^aff7, Zhu, Daoming^aff8, Lam, Jacky W. Y.^aff4, Huang, Qinqin^aff6, Zhang, Tianfu^{aff3, aff4}, Tang, Ben Zhong^{aff2, aff4}

Second-line chemotherapy rechallenge in lung cancer patients: a Moroccan real-world study

Hassan Abdelilah Tafenzi, Farah Choulli, Ismail Essadi, Rhizlane Belbaraka

electronic resource

Visa; Visa

Prevalence and management of immediate drug hypersensitivity observed during antineoplastic drug therapy

Trine Holm Rasmussen, Charlotte Gotthard Mortz, Per Pfeiffer, Nina Andersen, Carsten Bindslev-Jensen

electronic resource

Visa; Visa

Rechallenge with immune checkpoint inhibitors therapy for patients with HCC-lot more to learn

Lau, George^{Aff1, Aff2, IDs1207202410751w_cor1}

Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report

Tamellini, E.^{Aff1, IDs00277024059226_cor1}, Simio, C., Bernardelli, A., Ferrarini, I., Vatteroni, A., Moioli, A., Macaluso, V., Marchetti, E., Tanasi, I.^{Aff2, IDs00277024059226_cor9}